Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease (CREDO 1)
Rheumatoid Arthritis
About this trial
This is an interventional treatment trial for Rheumatoid Arthritis focused on measuring moderate Rheumatoid Arthritis, severe Rheumatoid Arthritis, subcutaneous, Olokizumab
Eligibility Criteria
Inclusion Criteria:
Subjects may be enrolled in the study only if they meet all of the following criteria:
- Subjects willing and able to sign informed consent
- Subjects must have a diagnosis of adult onset RA classified by ACR/EULAR 2010 revised classification criteria for RA for at least 12 weeks prior to Screening.
Inadequate response to treatment with MTX for at least 12 weeks prior to Screening at a dose of 15 to 25 mg/week (or ≥10 mg/week if intolerant to higher doses).
- The dose and means of administering MTX must have been stable for at least 6 weeks prior to Screening.
- Subjects must be willing to take folic acid or equivalent throughout the study
Subjects must have moderately to severely active RA disease as defined by all of the following:
- ≥6 tender joints (68 joint count) at Screening and baseline; and
- ≥6 swollen joints (66 joint count) at Screening and baseline; and
- CRP above ULN at Screening based on the central laboratory results.
Exclusion Criteria:
- Diagnosis of any other inflammatory arthritis or systemic rheumatic disease (e.g., gout, psoriatic or reactive arthritis, Crohn's disease, Lyme disease, juvenile idiopathic arthritis, or systemic lupus erythematosus). However, subjects may have secondary Sjogren's syndrome or hypothyroidism
- Subjects who are Steinbrocker class IV functional capacity (incapacitated, largely or wholly bed-ridden or confined to a wheelchair, with little or no self-care)
- Prior exposure to any licensed or investigational compound directly or indirectly targeting IL 6 or IL 6R (including tofacitinib or other Janus kinases and spleen tyrosine kinase [SYK] inhibitors)
- Prior treatment with cell depleting therapies including anti CD20 or investigational agents (e.g., CAMPATH, anti CD4, anti CD5, anti CD3, and anti CD19)
Prior use of bDMARDs, with the following exception:
• Subjects who discontinued TNFi therapy due to a reason other than lack of efficacy are allowed to enter the study (TNFi therapy should not be discontinued to facilitate a subject's participation in the study, but should instead have been previously discontinued as part of a subject's medical management of RA). The use of TNFi therapy within the following windows prior to baseline is exclusionary: i. 4 weeks for etanercept ii. 8 weeks for infliximab iii. 10 weeks for adalimumab, certolizumab, and golimumab
- Use of parenteral and/or intra-articular glucocorticoids within 4 weeks prior to baseline
- Use of oral glucocorticoids greater than 10 mg/day prednisone (or equivalent) or change in dosage within 2 weeks prior to baseline
- Prior documented history of no response to hydroxychloroquine and sulfasalazine
Prior use of cDMARDs (other than MTX) within the following windows prior to baseline (cDMARDs should not be discontinued to facilitate a subject's participation in the study, but should instead have been previously discontinued as part of a subject's medical management of RA):
- 4 weeks for sulfasalazine, azathioprine, cyclosporine, hydroxychloroquine, chloroquine, gold, penicillamine, minocycline, or d oxycycline
- 12 weeks for leflunomide unless the subject has completed the following elimination procedure at least 4 weeks prior to baseline: Cholestyramine at a dosage of 8 grams 3 times daily for at least 24 hours, or activated charcoal at a dosage of 50 grams 4 times daily for at least 24 hours
- 24 weeks for cyclophosphamide
- Vaccination with live vaccines in the 6 weeks prior to baseline or planned vaccination with live vaccines during the study
- Participation in any other investigational drug study within 30 days or 5 times the terminal half-life of the investigational drug, whichever is longer, prior to baseline
- Other treatments for RA (e.g., Prosorba Device/Column) within 6 months prior to baseline
- Use of intra-articular hyaluronic acid injections within 4 weeks prior to baseline
- Use of non-steroidal anti-inflammatory drugs (NSAIDs) on unstable dose or switching of NSAIDs within 2 weeks prior to baseline
- Previous participation in this study (randomized) or another study of OKZ
Abnormal laboratory values, as defined below:
- Creatinine level ≥ 1.5 mg/dL (132 µmol/L) for females or ≥ 2.0 mg/dL (177 µmol/L) for males
- ALT or AST level ≥ 1.5× ULN
- Platelets <100×10^9/L (<100,000/mm^3)
- White blood cell count <3.5×10^9/L
- Neutrophil count <2000×10^6/L (<2000/mm^3)
- Hemoglobin level ≤ 80 g/L
- Glycosylated hemoglobin (HbA1c) level ≥ 8%
Subjects with concurrent acute or chronic viral hepatitis B or C infection as detected by blood tests at Screening (e.g., positive for hepatitis B surface antigen [HBsAg], total hepatitis B core antibody [anti-HBc], or hepatitis C virus antibody [HCV Ab])
a) Subjects who are positive for hepatitis B surface antibody (anti-HBs), but negative for HBsAg and anti-HBc, will be eligible.
- Subjects with HIV infection
- Subjects with current active TB infection or a history of active TB infection
- Close contact (i.e., sharing the same household or other enclosed environment, such as a social gathering place, workplace, or facility, for extended periods during the day) with an individual with active TB within 1.5 years prior to Screening
History of untreated latent TB infection (LTBI), regardless of IGRA result at Screening i. Subjects with a history of untreated LTBI may be re-screened and enrolled if they fulfill all 3 of the following criteria:
- Active TB is ruled out by a certified TB specialist or pulmonologist who is familiar with diagnosing and treating TB (as acceptable per local practice);
- The subject has completed at least 30 days of LTBI-appropriate prophylaxis prior to baseline with agents recommended as preventative therapy for LTBI according to country-specific/Centers for Disease Control and Prevention (CDC) guidelines (treatment with isoniazid for 6 months is not an appropriate prophylactic regime for this study and it should not be used); and
- The subject is willing to complete the entire course of recommended LTBI therapy
Positive interferon-gamma release assay (IGRA) result at Screening. If indeterminate, the IGRA can be repeated once during the Screening Period. If there is a second indeterminate result, the subject will be excluded.
i. Subjects with a positive IGRA result at Screening may be re-screened and enrolled if they fulfill all 3 of the following criteria:
- Active TB is ruled out by a certified TB specialist or pulmonologist who is familiar with diagnosing and treating TB (as acceptable per local practice);
- The subject has completed at least 30 days of LTBI-appropriate prophylaxis prior to baseline with agents recommended as preventative therapy for LTBI according to country-specific/CDC guidelines (treatment with isoniazid for 6 months is not an appropriate prophylactic regime for this study and it should not be used); and
The subject is willing to complete the entire course of recommended LTBI therapy.
ii.If a subject with a positive IGRA result at Screening has documented evidence of completing treatment for LTBI with a treatment regime and treatment duration that are appropriate for this study, the subject may be enrolled without further prophylaxis if recommended by a certified TB specialist or pulmonologist who is familiar with diagnosing and treating TB (as acceptable per local practice) and no new exposure in close contact with an individual with active TB after completing the prophylactic treatment is suspected
- Concurrent malignancy or a history of malignancy within the last 5 years (with the exception of successfully treated carcinoma of the cervix in situ and successfully treated basal cell carcinoma and squamous cell carcinoma not less than 1 year prior to Screening [and no more than 3 excised skin cancers within the last 5 years prior to Screening])
Subjects with any of the following CV conditions:
- Uncompensated congestive heart failure, or class III or IV heart failure defined by the New York Heart Association classification (The Criteria Committee of the New York Heart Association, 1994)
- Untreated or resistant arterial hypertension Grade II-III (systolic blood pressure [BP] > 160 mm Hg and/or diastolic BP >100 mm Hg)
- History or presence of concurrent severe and/or uncontrolled CV disorder (including but not limited to acute coronary syndrome or stroke/transient ischemic attack in the previous 3 months before Screening) that would, in the Investigator's judgment, contraindicate subject participation in the clinical study, or clinically significant enough in the opinion of the Investigator to alter the disposition of the study treatment, or constitute a possible confounding factor for assessment of efficacy or safety of the study treatment
- Subjects with a history or presence of any concurrent severe and/or uncontrolled medical condition (including but not limited to respiratory, hepatic, renal, GI, endocrinological, dermatological, neurological, psychiatric, hematological [including bleeding disorder], or immunologic/immunodeficiency disorder[s]) that would, in the Investigator's judgment, contraindicate subject participation in the clinical study, or clinically significant enough in the opinion of the Investigator to alter the disposition of the study treatment, or constitute a possible confounding factor for assessment of efficacy or safety of the study treatment
- Uncontrolled diabetes mellitus
- Subjects with any infection requiring oral antibiotic or antiviral therapy in the 2 weeks prior to Screening or at baseline, injectable anti-infective therapy in the last 4 weeks prior to baseline, or serious or recurrent infection with history of hospitalization in the 6 months prior to baseline
- Subjects with evidence of disseminated herpes zoster infection, zoster encephalitis, meningitis, or other non-self-limited herpes zoster infections in the 6 months prior to baseline
- Subjects with planned surgery during the study or surgery ≤4 weeks prior to Screening and from which the subject has not fully recovered, as judged by the Investigator
- Subjects with diverticulitis or other symptomatic GI conditions that might predispose the subject to perforations, including subjects with a history of such predisposing conditions (e.g., diverticulitis, GI perforation, or ulcerative colitis)
- Pre-existing central nervous system demyelinating disorders (e.g., multiple sclerosis and optic neuritis)
- History of chronic alcohol or drug abuse as judged by the Investigator
- Female subjects who are pregnant, currently lactating, have lactated within the last 12 weeks, or who are planning to become pregnant during the study or within 6 months of last dose of study treatment
- Female subjects of childbearing potential (unless permanent cessation of menstrual periods, determined retrospectively after a woman has experienced 12 months of natural amenorrhea as defined by the amenorrhea with underlying status [e.g., correlative age] or 6 months of natural amenorrhea with documented serum follicle-stimulating hormone levels >40 mIU/mL and estradiol <20 pg/mL) who are not willing to use a highly effective method of contraception during the study OR Male subjects with partners of childbearing potential not willing to use a highly effective method of contraception during the study and for at least 3 months after the last administration of study treatment
- Subjects with a known hypersensitivity to any component of the OKZ drug product, or placebo
- History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies
- Subject's unwillingness or inability to follow the procedures outlined in the protocol
- Other medical or psychiatric conditions or laboratory abnormalities that may increase potential risk associated with study participation and administration of investigational products, or that may affect study results interpretation and, as per the Investigator's judgment, make the subject ineligible
Sites / Locations
- City Clinical Hospital #1
- Vitebsk Regional Clinical Hospital
- DCC 'Sv. Pantaleymon' OOD
- UMHAT "Kaspela", EOOD
- UMHAT "Sv. Ivan Rilski", EAD
- MC "Synexus - Sofia", EOOD
- Regional State Budgetary Healthcare Institution "Barnaul City Hospital #4"
- Medical Center LLC "Maksimum Zdoroviya"
- SAHI of Kemerovo region "Regional Clinical Hospital for War Veterans"
- Budgetary Healthcare Institution "Kursk Regional Clinical Hospital" of Healthcare Committee of Kursk region
- SPb SBHI "Clinical Rheumatological Hospital #25", Fourth Rheumatology Unit
- FSBEI HE "First Moscow State Medical University n.a. I.M. Sechenov of MoH of Russian Federation", UCH #1
- FSBEI HE "FMSMU n.a. I.M. Sechenov of MoH of RF", University Hospital #2, Departament of New Drugs Introduction
- SBEI HPE "First Moscow State Medical University n.a. I.M. Sechenov of MoH of Russian Federation" UCH #3
- State Budgetary Healthcare Institution of Moscow "City Clinical Hospital #1 n.a. Pirogov" Healthcare Departament of Moscow
- State Budgetary Healthcare Institution "City Clinical Hospital # 15 n.a O.M. Filatov" of Moscow Healtheare Department
- SBHI of Moscow "City Clinical Hospital #4 of Moscow Healthcare Departament"
- SBHI of Nizhny Novgorod Region "Nizhny Novgorod Regional Clinical Hospital n.a.Semashko"
- State Autonomous Healthcare Institution of Novosibirsk region "City Polyclinic #1"
- LLC "Clinical Diagnostic Center "Ultramed"
- Budgetary Healthcare Institution of Omsk Region "Regional Clinical Hospital"
- SBHI of the Republic of Karelia "Republican Hospital named after V.A. Baranov"
- State Budgetary Healthcare Institution "Republican Clinical Hospital n.a. G.G. Kuvatov"
- SBEI HPE "Rostov State Medical University" of Ministry of Health of the Russian Federation
- State Healthcare Institution "Regional Clinical Hospital"
- SBEI HPE "SSMU n.a. V.I. Razumovsky of MoH of RF", Clinical Hospital n.a. S.R. Mirotvorcev, Therapeutic Departament
- Non-governmental Healtheare Institution "Regional Clinical Hospital at Smolensk station of OJSC "Russian Railways"
- SBHI of Stavropol Region "Stavropol Regional Clinical Hospital"
- State Budgetary Healthcare Institution of Sverdlovsk Region "Sverdlovsk Regional Clinical Hospital #1"
- SBEI HPE "Ural State Medical University" of MoH of RF based MBI "Central City Clinical Hospital #6"
- State Autonomous Healthcare Institution "Republican Clinical Hospital of Ministry of Health of Tatarstan Republic
- State Healthcare Institution of Tula region "Tula Regional Clinical Hospital"
- State Healthcare Institution "Ulyanovsk Regional Clinical Hospital"
- SBHI of Vladimir Region "Regional Clinical Hospital", Rheumatology Departament
- State Autonomous Helthcare Institution of Yaroslavl region "Clinical Hospital of Emergency Care n.a. Solovyev"
- SBHI "Yaroslavl Regional Clinical Hospital", Rheumatology department
- FSBSI "Scientific Research Institute of Rheumatology n.a. V.A. Nasonova"
- City Clinical Hospital №5 of Nizhny Novgorod
- Ryazan State Medical University n.a. I.P. Pavlov based on Regional Clinical Cardiology Dispensary
- SBHI "North-West Federat Medical Research Center n.a. V.A.Almazov" of the Ministry of Healthcare of the Russian Federation
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Placebo Comparator
Arm 1: Olokizumab q4w
Arm 2: Olokizumab q2w
Arm 3: Placebo
Olokizumab 64 mg Subcutaneous q4w +placebo+ Methotrexate (oral) in order to maintain the blind, subjects randomized to receive OKZ q4w will receive placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.)
Olokizumab 64 mg Subcutaneous q2w + Methotrexate (oral)
Placebo Subcutaneous q2w + Methotrexate (oral)